Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 8/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.50 |
| ▸ | GABRP | O00591 | 3/20 | 0.50 |
| ▸ | GABRD | O14764 | 3/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.50 |
| ▸ | GABRE | P78334 | 3/20 | 0.50 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.50 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.50 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.50 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16584769 | 1.00 | PIK3CD (0.50) | PIK3CDPIK3CGGABRPGABRDGABRA1 | |
| SCHEMBL16589442 | 1.00 | PIK3CD (0.50) | PIK3CDPIK3CGGABRPGABRDGABRA1 | |
| SCHEMBL28815080 | 0.91 | GABRP (0.51) | PIK3CDPIK3CGGABRPGABRDGABRA1 | |
| SCHEMBL29837040 | 0.91 | GABRP (0.51) | PIK3CDPIK3CGGABRPGABRDGABRA1 | |
| SCHEMBL28815081 | 0.91 | GABRP (0.51) | PIK3CDPIK3CGGABRPGABRDGABRA1 | |
| SCHEMBL15528006 | 0.88 | PIK3CD (0.52) | PIK3CDPIK3CGGABRPGABRDGABRA1 | |
| SCHEMBL15599908 | 0.88 | PIK3CD (0.50) | PIK3CDPIK3CGGABRPGABRDGABRA1 | |
| SCHEMBL15599907 | 0.88 | PIK3CD (0.50) | PIK3CDPIK3CGGABRPGABRDGABRA1 | |
| SCHEMBL16458233 | 0.88 | PIK3CD (0.52) | PIK3CDPIK3CGGABRPGABRDGABRA1 | |
| SCHEMBL15599851 | 0.88 | PIK3CD (0.52) | PIK3CDPIK3CGGABRPGABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11478481-B2 | Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals | RHIZEN PHARMACEUTICALS AG (CH) | 2022-10-25 | — | — | US | disclosed |
| EP-2844647-B1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS S A (CH) | 2020-07-22 | — | — | EP | disclosed |
| US-20190038634-A1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS AG (CH) | 2019-02-07 | — | — | US | disclosed |
| US-10130635-B2 | Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals | RHIZEN PHARMACEUTICALS SA (CH) | 2018-11-20 | — | — | US | disclosed |
| US-20180098994-A9 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS AG (CH) | 2018-04-12 | — | — | US | disclosed |
| US-20170266196-A1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS SA (CH) | 2017-09-21 | — | — | US | disclosed |
| US-9309216-B2 | Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals | RHIZEN PHARMACEUTICALS SA (CH) | 2016-04-12 | — | — | US | disclosed |
| US-20150087699-A1 | NOVEL PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS AG (CH) | 2015-03-26 | — | — | US | disclosed |
| EP-2844647-A1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2- (1 -HYDROXY- ALKYL) - CHROMEN - 4 - ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | Rhizen Pharmaceuticals S.A. (CH) | 2015-03-11 | — | — | EP | disclosed |
| WO-2013164801-A1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2- (1 -HYDROXY- ALKYL) - CHROMEN - 4 - ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS SA (CH) | 2013-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038634-A1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | CYP4B1, ADH1A, CYP1A2 | PIK3CD 516/4885PIK3CG 636/4885GABRP 1470/4885 |
| US-20150087699-A1 | NOVEL PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | CYP4B1, ADH1A, CYP1A2 | PIK3CD 561/4885PIK3CG 735/4885GABRP 1672/4885 |
| US-11478481-B2 | Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals | CYP4B1, ADH1A, CYP1A2 | PIK3CD 516/4885PIK3CG 636/4885GABRP 1470/4885 |
| US-20180098994-A9 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | CYP4B1, ADH1A, CYP1A2 | PIK3CD 516/4885PIK3CG 636/4885GABRP 1470/4885 |
| US-20170266196-A1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | CYP4B1, ADH1A, CYP1A2 | PIK3CD 516/4885PIK3CG 636/4885GABRP 1470/4885 |
| US-10130635-B2 | Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals | CYP4B1, ADH1A, CYP1A2 | PIK3CD 516/4885PIK3CG 636/4885GABRP 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.